TNYA

Tenaya TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.25

+58.2% vs current

Most likely

Base case

45%

Probability

Target price

$0.65

-17.7% vs current

B-

Bear case

30%

Probability

Target price

$0.30

-62.0% vs current

AI sentiment snapshot

Latest data as of 2026-05-04

AI commentary

As of May 4, 2026, Tenaya’s checked company materials did not provide a confirmed Q1 2026 earnings package, so this scheduled post-earnings T+3 run lacks a verified earnings surprise, guidance revision, or updated cash-burn readout. The repair adds the March 5, 2026 primary company release on the Alnylam collaboration as a distinct long-horizon partnership catalyst, but that evidence supports monitoring language rather than a stronger thesis because the economics are contingent and the usable peer set remains limited to TN-401-specific comparators. With a negative deterministic prior, low coverage, and no verified fresh analyst target changes in the packet, confidence remains cautious despite meaningful clinical optionality.

RankAlpha Sentiment Codex - 2026-05-04

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-05-15eventRIDGE-1 late-breaking ASGCT data on May 15High impact

Tenaya said on April 27, 2026 that its late-breaking ASGCT 2026 presentation for TN-401 will include new safety, biopsy and efficacy data from both dose cohorts in RIDGE-1, with the oral presentation scheduled for May 15, 2026 and a management webcast planned; because TN-401 is one of the company’s clearest near-term value drivers, this is the most immediate stock-moving checkpoint [#PR-2026-04-27].

2026-06-30eventTN-201 H1 2026 follow-up remains a second binary readoutHigh impact

Tenaya’s 2026 10-K says it expects longer-term Cohort 1 data and interim Cohort 2 data for TN-201 in the first half of 2026, leaving another meaningful clinical checkpoint before June-end if management stays on schedule [#10-K-2026-03-11].

2026-07-27catalystNasdaq bid-price deadline and financing optics remain an overhangHigh impact

Tenaya’s January 26, 2026 8-K says Nasdaq gave the company until July 27, 2026 to regain compliance with the $1.00 minimum bid-price rule; with the anchor price at $0.7058 on May 1, 2026, reverse-split or financing optics remain a near-term pressure point even though the March 11, 2026 10-K said year-end 2025 cash should fund operations for at least the next twelve months from filing [#8-K-2026-01-26] [#10-K-2026-03-11].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-04 • Updated nightlySource: Internal modelMethodology